Several participants expressed a desire for increased availability of the medication to other people, and were aware that the funding was only for a limited period
Growth hormone secretagogues and IGF-1 analogues stimulate anabolism in muscle, while GLP-1 analogues suppress calorie intake
We start with a full hormone panel via blood draw, then design a treatment plan based on results
While we await findings from bigger studies, its difficult to interpret the conflicting results
71.2 lbs on average) Retatrutide 9mg: 26.4% body weight reduction Tirzepatide/Zepbound (Phase 3 comparison, not head-to-head): ~20.9% Semaglutide/Wegovy (Phase 3 comparison, not head-to-head): ~14.9% Placebo: ~2.1% Note: These figures come from separate Phase 3 trials and are not direct head-to-head comparisons
Key players today include Mounjaro (tirzepatide) a dual-agonist of GLP-1 and GIP receptors and coming soon, Retatrutide a triple-receptor agonist (GLP-1, GIP and glucagon) that has shown even stronger early results
